Новости ФармаМондо Archives

Mirum pharmaceuticals and FarmaMondo Group enter into an exclusive commercialization agreement for Russia and CIS region

16 ноября, 202110 сентября, 2021

Mirum Pharmaceuticals (NASDAQ: MIRM) and FarmaMondo entered into an exclusive distribution and supply agreement appointing the FarmaMondo Group as the exclusive partner to make their

Ideogen AG and FarmaMondo enter into a managed access program agreement to allow Fotolyn, Beleodaq and Marqibo distribution in Russia, CIS market and Baltics

30 ноября, 202126 июля, 2021

Ideogen AG and FarmaMondo enter into an exclusive Managed Access Program distribution agreement appointing the FarmaMondo Group as the exclusive partner for their innovative PTCL

FarmaMondo announces the establishment of FarmaMondo JAPAC hub, in Singapore

6 мая, 202115 апреля, 2021

The FarmaMondo Group announces the establishment of FarmaMondo Pte, a fully owned subsidiary in Singapore. FarmaMondo Pte Singapore will further serve the Group’s development strategy

FarmaMondo announces the establishment of FarmaMondo Iberia, in Portugal

6 мая, 202112 февраля, 2021

February 2021 FarmaMondo SA announces the establishment of FarmaMondo Iberia, in Portugal, a fully owned subsidiary of FarmaMondo SA. The Iberian Subsidiary will further enhance

Sarepta Therapeutics and FarmaMondo announce an agreement to exclusively manage access of eteplirsen and golodirsen in Russia

10 мая, 202127 декабря, 2020

December 2020 – FarmaMondo SA announced an exclusive distribution of eteplirsen and golodirsen for certain patients with Duchenne muscular dystrophy (DMD) in Russia. FarmaMondo SA,

Dompe’ farmaceutici and the FarmaMondo Group: exclusive agreement to distribute oxervate™ in Russia and other CIS countries

6 мая, 202110 ноября, 2020

November 2020 – Dompé farmaceutici Spa and FarmaMondo entered into an exclusive Managed Access Program distribution agreement appointing the FarmaMondo Group as the exclusive partner

FarmaMondo new website is now LIVE!

6 мая, 202119 июня, 2020

FarmaMondo is pleased to announce the launch of its brand new website! After months of hard work and dedication, we are delighted to officially announce

Zion Medical appoints the FarmaMondo Group to support global named patient access to its novel therapy Gammora™

15 февраля, 20225 июня, 2020

FarmaMondo and Zion Medical, an Israel startup pharma developer, signed today an agreement to establish a MAP for their novel drug Gammora. The product is

FarmaMondo to exclusively manage access to Metreleptin (Myalept®) by Amryt Pharma for patients with lipodystrophy in CIS (excluding Russia)

1 апреля, 20211 июня, 2020

Amryt Pharma (www.amrytpharma.com/) has appointed FarmaMondo, the world’s leader in paid-access to unlicensed medicines, to exclusively manage the access of its innovative therapy Metreleptin (FDA/EMA approval under

EUSA and FarmaMondo Group establishes an Emergency Managed Access Program to allow Healthcare Providers to access Siltuximab (Sylvant©) for off label treatment of acute patients of COVID-19

1 апреля, 202114 апреля, 2020

While the world fights through COVID19 pandemic EUSA and Papa Giovani Hospital in Italy had initiated an observational study (SISCO trial — https://clinicaltrials.gov/ct2/show/NCT04322188?term=SISCO&draw=2&rank=1) on Siltuximab

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Analytics" category .
cookielawinfo-checkbox-functional	1 year	The cookie is set by the GDPR Cookie Consent plugin to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Necessary" category .
cookielawinfo-checkbox-others	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to store the user consent for cookies in the category "Others".
cookielawinfo-checkbox-performance	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to store the user consent for cookies in the category "Performance".

Cookie	Duration	Description
VISITOR_INFO1_LIVE	5 months 27 days	A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSC	session	YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.
yt-remote-connected-devices	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt-remote-device-id	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt.innertube::nextId	never	This cookie, set by YouTube, registers a unique ID to store data on what videos from YouTube the user has seen.
yt.innertube::requests	never	This cookie, set by YouTube, registers a unique ID to store data on what videos from YouTube the user has seen.

Cookie	Duration	Description
CONSENT	2 years	YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_gat_gtag_UA_168675207_1	1 minute	Set by Google to distinguish users.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.